Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

TORONTO -- Achieving minimal residual disease (MRD) negativity was associated with favorable safety outcomes and no effect on health-related quality of life among patients with newly diagnosed ...

Personalis has high upside potential if its MRD test gains Medicare reimbursement, but current revenue and margins are under pressure. The company faces declining pharma revenue, sustained cash burn, ...

The FDA's Breakthrough Devices Program accelerates access to promising medical devices for serious conditions, ensuring safety and effectiveness through a rigorous review process. Haystack MRD test ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted breakthrough device designation to Quest Diagnostics’ Haystack MRD test for identifying patients ...

Panelists discuss how measurable residual disease (MRD) testing should be used primarily for prognostic information rather than routine treatment decision-making, with current guidelines recommending ...

MILAN — The landscape of hematologic malignancies is shifting rapidly, in part due to the evolving significance of measurable (formerly "minimal") residual disease (MRD). Once confined to the realm of ...

Adaptive Biotechnologies Corporation announced that its clonoSEQ® test for measurable residual disease (MRD) will be prominently featured in 30 presentations at the upcoming American Society of ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

Adaptive Biotechnologies and NeoGenomics have announced a multi-year strategic collaboration to enhance minimal residual disease (MRD) monitoring for patients with specific blood cancers. The ...

DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb Genomics, a pioneer in single-cell and ultra-low input multiomics is excited to announce the launch of ResolveSEQ MRD, an innovative service offering designed ...

MRD status before allo-HSCT is a strong prognostic factor for OS, DFS, and CIR in AML and MDS patients. MRD-negative patients showed significantly better OS and DFS compared to MRD-positive patients, ...